In a report released today, Josh Jennings from TD Cowen reiterated a Buy rating on Stereotaxis, with a price target of $5.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on the promising initial results of Stereotaxis’ MAGiC catheter. The catheter has demonstrated a 94% acute efficacy rate and strong safety profile across a variety of arrhythmias, which is a significant indicator of its potential success.
Furthermore, the favorable workflow metrics and positive feedback from physicians highlight the performance benefits of the MAGiC catheter. These factors collectively support the continued rollout in Europe and bolster its prospects as a next-generation robotic ablation solution, reinforcing the Buy rating.